Try our beta test site
2397 studies found for:    EGFR
Show Display Options
Rank Status Study
21 Not yet recruiting Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Condition: Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer
Intervention: Drug: Chidamide with EGFR-TKI
22 Not yet recruiting Endostar Plus EGFR-TKI(Epidermal Growth Factor Receptor—Tyrosine-Kinase Inhibitor) as a Treatment of EGFR Mutation-positive NSCLC
Conditions: Advanced Cancer;   Lung Cancer, Nonsmall Cell
Intervention: Drug: EGFR-TK Inhibitor
23 Completed Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
Condition: Non-small Cell Lung Cancer Metastatic
Intervention: Biological: CTC
24 Recruiting Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc
Condition: Advanced Stage Non Small Cell Lung Cancer
Interventions: Drug: Erlotinib 100mg qd;   Drug: Gefitinib 250mg qd
25 Completed Europe-Japan Diagnostic Study for EGFR Testing
Condition: EGFR Mutation Status in aNSCLC Patients (Locally Advanced and/or Metastatic Disease) With Adenocarcinoma and Non-adenocarcinoma Histologies.
Intervention:
26 Completed Efficacy Analysis of Cetuximab Plus Irinotecan in Patients With Wild-type KRAS Without Regard to Epidermal Growth Factor Receptor (EGFR) Expressions
Condition: Advanced Colorectal Cancer
Intervention: Drug: Cetuximab, irinotecan
27 Terminated A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
Condition: EGFR Positive Solid Tumors
Intervention: Drug: IMGN289
28 Completed Detecting EGFR T790M Mutations From Circulating Tumor Cells
Condition: Non Small Cell Lung Cancer
Intervention: Device: Circulating tumor cell chip
29 Unknown  Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC
Condition: Asymptomatic Brain Metastases of Non Small Cell Lung Cancer
Intervention: Drug: EGFR-TKI
30 Recruiting Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)
Condition: Stage IV EGFR Mutated NSCL With Brain Metastases
Interventions: Drug: Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib;   Radiation: WBRT;   Radiation: HFSRS
31 Recruiting Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC
Condition: Non Small Cell Lung Cancer
Interventions: Drug: EGFR-TKIs;   Radiation: thoracic radiotherapy
32 Completed Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m
Condition: Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer
Intervention:
33 Recruiting Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study
Condition: EGFR Mutation Positive Non Small Cell Lung Cancer
Intervention:
34 Recruiting Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA
Conditions: Lung Neoplasms;   EGFR Gene Mutations
Intervention: Drug: Osimertinib
35 Not yet recruiting EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: EGFR-TKI;   Drug: Chemotherapy(pemetrexed/gemcitabine);   Drug: Chemotherapy(carboplatin)
36 Unknown  Observational Study to Characterize the Incidence of EGFR Mutation Positive and Advanced NSCLC Patients
Condition: Metastatic Non-Small-Cell Lung Cancer
Intervention:
37 Recruiting PANORAMA - Real World Molecular Testing, Treatment Patterns, and Clinical Outcomes EGFR Mutation-Positive NSCLC
Condition: Carcinoma, Non-Small-Cell Lung
Intervention:
38 Not yet recruiting Clinical Trial of YH25448 in Patients With EGFR Mutation Positive Advanced NSCLC
Condition: EGFR Gene Mutation
Intervention: Drug: YH25448
39 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Conditions: NSCLC;   EGFR Mutation
Intervention: Drug: Erlotinib
40 Recruiting TORC1/2 Inhibitor INK128 and EGFR Inhibitor AZD9291 in Treating Patients With Advanced EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase Inhibitor
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Osimertinib;   Other: Pharmacological Study;   Drug: Sapanisertib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.